synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
==== Miscellaneous euarchontoglires research ==== Zhang & Wang (2026) revise and study the affinities of fossil lagomorphs from China. A study on the anatomy and affinities of Gymnesicolagus gelaberti is published by Čermák et al. (2026). Zhang & Wang (2026) describe new fossil material of Desmatolagus gobiensis from the Oligocene strata from the Ulantatal site (Inner Mongolia, China) and study the phylogenetic relationships of the species, interpreting it as a basal member of Ochotonidae. Kalaitzi & Kostopoulos (2026) study the forelimb and hindlimb morphology of Trischizolagus dumitrescuae, interpreted as indicative of adaptations for controlled, agile leaping, as well as indicative of more developed running abilities compared to typical rabbits but without the extreme specialization seen in hares. Chester et al. (2026) report the discovery of fossil material of Purgatorius from the Denver Formation (Colorado, United States), representing the first record of a Puercan plesiadapiform south of Montana reported to date. Evidence from the study of virtual endocasts of extant and extinct members of Euarchontoglires, indicative of a shared ancestral endocranial shape in early members of the group, indicating that treeshrews are not a good model for the ancestral endocranial shape in Euarchontoglires, and indicating that primates evolved their modern endocranial morphologies faster than other members of Euarchontoglires, is presented by Lang et al. (2026)
Notable is the mention of cystoceles in many older cultures and locations. In 1500 B.C. Egyptians wrote about the "falling of the womb". In 400 B.C., a Greek physician documented his observations and treatments: "After the patient had been tied to a ladder-like frame, she was tipped upward so that her head was toward the bottom of the frame. The frame was then moved upward and downward more or less rapidly for approximately 3–5 min. As the patient was in an inverted position, it was thought that the prolapsing organs of the genital tract would be returned to their normal position by the force of gravity and the shaking motion." Hippocrates thought that recent childbirth, wet feet, 'sexual excesses', exertion, and fatigue may have contributed to prolapse. Polybus, Hippocrates's son-in-law, wrote: "a prolapsed uterus was treated by using local astringent lotions, a natural sponge packed into the vagina, or placement of half a pomegranate in the vagina." In 350 A.D., another practitioner named Soranus described his treatments, which stated that the pomegranate should be dipped into vinegar before insertion. Success could be enhanced if the woman were on bed rest and had reduced food and fluid intake. If the treatment was still not successful, the woman's legs were tied together for three days. In 1521, Berengario da Carpi performed the first surgical treatment for prolapse. This was to tie a rope around the prolapse, tighten it for two days until it was no longer viable, and cut it off. Wine, aloe, and honey were then applied to the stump.
For example, the pattern may be 10 press ups, then two minutes rest, 10 press ups, then two minutes rest etc. The ability to recover during an exercise (active recovery), during a training session, and resting between training sessions are all of fundamental importance in strength training. If recovery cannot take place then fatigue may occur leading to worse performance and an increased chance of injury.
Sources: en.wikipedia.org
Sunak announces that former prime minister Johnson will endorse Conservative candidates by writing to constituents urging them not to vote for Reform, saying to do so will "make a difference". The state visit of Japan's Emperor Naruhito is to be modified to omit the usual visit to 10 Downing Street because it coincides with the election. Scottish Labour launches its general election manifesto. Businessman John Caudwell, the founder of Phones4U, who gave the Conservatives a £500,000 donation before the 2019 general election, tells the BBC he will be voting Labour for the first time in his life at the 2024 election. During an election debate on BBC Radio 4's Woman's Hour, representatives from Labour, the Liberal Democrats, Greens and Scottish National Party express their support for making misogyny a hate crime. 19 June – A police officer working as part of the prime minister's close protection team is suspended and later arrested as part of an ongoing investigation into bets on the date of the general election. The Scottish National Party launches its election manifesto, with plans to "end Westminster cuts" and increase investment in the NHS. The party would also view winning a majority of Scotland's seats at Westminster as a mandate to begin independence negotiations. Labour suspends Andy Brown, its candidate for Aberdeenshire North and Moray East after he was found to have shared pro-Russian posts online. The Scottish Family Party launches its election manifesto, chiefly promoting family values.
5-Hydroxyeicosanoid dehydrogenase (5-HEDH) or more formally, nicotinamide adenine dinucleotide phosphate (NADP+)-dependent dehydrogenase, is an enzyme that metabolizes between two eicosanoid metabolites of arachidonate 5-lipoxygenase (5-LOX): 5-hydroxyeicosatetraenoic acid (5-(S)-HETE), and its 5-keto analog 5-oxo-eicosatetraenoic acid (5-oxo-ETE). It also acts in the reverse direction, metabolizing 5-oxo-ETE to 5(S)-HETE. Since 5-oxo-ETE is 30–100-fold more potent than 5(S)-HETE in stimulating various cell types, 5-HEDH is regarded as a regulator and promoter of the influence that 5-LOX and its metabolites have on cell function. Although 5-HEDH has been evaluated in a wide range of intact cells and in crude microsome preparations, it has not yet been evaluated for its structure or gene, and most studies on it have been limited to human tissues.
Troika, unable to obtain further funding from Activision or other publishers, released its employees in two waves: the first in November 2004, followed by the remaining staff in December, except for its three founders, Anderson, Boyarsky, and Tim Cain. Some employees worked without pay to fix the game. When the company closed in February 2005, it had secured no other game development deals. That month, Boyarsky confirmed that Troika had not been working on a patch for the game since most of its staff had been gone since December 2004. In a 2006 interview, Anderson said that although Troika Games's library had been critically well received, consistent technical issues had marred the perception of the company's games, contributing to Troika's difficulty in obtaining new projects. In 2013, Mitsoda said that Bloodlines was released at "the worst possible time - most people didn't even know we were out ... fans and the Troika [developers] are always going to wonder what the game could have been like with another six months." In a 2017 interview, Boyarsky echoed Mitsoda's sentiments, saying that a further three to six months of development time could have allowed Troika to address many technical flaws, but he was unsure that they could have resolved larger issues. He said, "I feel the second half of the game isn't as good as the first. I feel like we devolved into relying too much on combat at the end." Boyarsky noted that it was impossible to know if the fixes would have made Bloodlines more successful or if it would have remained a niche product.
== Medical uses == Pioglitazone is used to lower blood glucose levels in type 2 diabetes either alone or in combination with sulfonylurea, metformin, or insulin. The effects of pioglitazone have been compared in a Cochrane systematic review to that of other blood sugar lowering-medicine, including metformin, acarbose, and repaglinide, as well as with appropriate diet and exercise, not showing any benefit in reducing the chance of developing type 2 diabetes in people at risk. It did, however, show reduction of risk of developing type 2 diabetes when compared to a placebo or to no treatment. These results should be interpreted considering that most of the data of the studies included in this review were of low or very-low certainty. While pioglitazone does decrease blood sugar levels, the main study that looked at the medication found no difference in the main cardiovascular outcomes that were looked at. The secondary outcome of death from all causes, myocardial infarction, and stroke were lower. Pioglitazone has been found to reduce all-cause mortality in type 2 diabetic patients compared to other therapies, with a 60% reduction in mortality in those exposed to pioglitazone, compared to those never exposed. Another study found an all-cause mortality hazard ratio of 0.33 for pioglitazone after adjusting for >40 covariates, compared to insulin. Due to insufficient data on all-cause mortality, cardiovascular mortality, myocardial infarction and stroke, this was not possible to compare in a more recent review.
Sources: en.wikipedia.org
=== Assisted reproduction === PRP can be inoculated into the uterine cavity, to improve endometrial receptivity in cases of refractory endometrium. Studies have reported that intrauterine inoculation of PRP before embryo transfer can thicken the endometrium and improve reproductive prognosis. PRP has been studied for the management of Asherman's Syndrome. PRP can be inoculated experimentally into the ovary to promote ovarian tissue regeneration. The main applications would be in cases of diminished ovarian reserve or premature ovarian failure. A 2023 retrospective observational study reported PRP's effectiveness in rejuvenating ovarian fertility and viability in terms of "the influence of intraovarian injection of autologous PRP on the levels of E2". and pregnancy outcome in women treated with PRP who had a history of infertility, hormonal abnormalities, an absence of menstrual cycle, and premature ovarian failure in a single centre." A 2024 review showed that PRP is beneficial when used as intraovarian injections for women with decreased fertility. PRP used for fertility trouble increases AFC, number of cleavage embryos, and improves cancellation rate in women with poor ovarian reserve. However, "Although there was an improvement of baseline hormones (anti-Müllerian hormone, follicle-stimulating hormone, and estradiol) after intraovarian injection of PRP, this improvement failed to reach statistical significance (except the improvement of serum AMH analyzed in quasi-experimental studies)."
=== France === This data pertains to reported medical cases of 23 specific pathogens in the 1990s, as opposed to total population estimates of all foodborne illness for the United States. In France, for 735,590 to 769,615 cases of infection identified as being with the 23 specific pathogens, 238,836 to 269,085 were estimated to have been contracted from food:
During protests against ICE operations in Portland, United States, some protesters flew the flag. The flag also saw use during the anti-Trump No Kings 2.0 protests in October 2025, e.g. in Los Angeles, Miami, and Spokane. In Mexico in November 2025, the flag was among various symbols used by a group identifying itself as "Generation Z Mexico", who is against drug violence that claims tens of thousands of Mexican lives each year and the security policies of Mexican president Claudia Sheinbaum. Former Mexican president Vicente Fox wore a T-shirt emblazoned with the symbol while attending the protests. Bulgarians protesting against increases in pension and social security payments in November–December 2025 used the flag. The flag was seen during the "Flamingo Revolution" in Albania. In August 2026, the Straw Hat Pirates' Jolly Roger was spray-painted on the National Monument on Dam Square in Amsterdam, alongside the phrases "Time to wake up!" and "Stop the human trafficking".
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.